MP0250, a VEGF and HGF neutralizing DARPin® molecule shows high anti-tumor efficacy in mouse xenograft and patient-derived tumor models

// Ulrike Fiedler 1 , Savira Ekawardhani 1 , Andreas Cornelius 1 , Pat Gilboy 1, 2 , Talitha R. Bakker 1, 3 , Ignacio Dolado 1, 4 , Michael T. Stumpp 1 and Keith M. Dawson 1 1 Molecular Partners AG, Schlieren, Switzerland 2 Horizon Pharma, Dublin, Ireland 3 Amgen (Europe) GmbH, Zug, Switzerland 4 Roche, Basel, Switzerland Correspondence to: Keith M. Dawson, email: info@molecularpartners.com Keywords: VEGF, HGF, serum albumin, DARPin ® ,...